PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), targeting programmed cell death-1 (PD-1) and its ligand PD-L1, have significantly prolonged overall survival (OS) of patients with advanced non-small cell lung cancer (NSCLC) (1, 2).